Additionally, an autopsy-based study reported different biochemical properties between TDP-43 aggregates of AD patients and those of FTLD-TDP patients; neuronal cytoplasmic or neuritic TDP-43 aggregates in AD patients demonstrated a varied immunoreactivity for full-length TDP-43, phosphorylated TDP-43 s402/403, or phosphorylated TDP-43 s409/410 among individuals, whereas TDP-43 aggregates in FTLD-TDP patients consistently showed immunoreactivity for all molecular forms of TDP-43 [78]. This evidence concerns the gene TARDBP and Alzheimer disease.